Equities

Dominari Holdings Inc

Dominari Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.30
  • Today's Change0.05 / 2.22%
  • Shares traded13.83k
  • 1 Year change-28.79%
  • Beta0.9255
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Dominari Holdings Inc. is a holding company. The Company, through its various subsidiaries, is engaged in wealth management, investment banking, sales and trading and asset management. It operates through its wholly owned subsidiaries, including Dominari Financial Inc. (Dominari Financial) and Dominari Securities LLC (Dominari Securities). Dominari Securities offers and plans to offer a range of broker-dealer and registered investment adviser services. Its services include wealth management, investment banking, sales and trading, asset management and insurance products. Dominari Securities provides a comprehensive array of financial services to high-net-worth individuals and families, corporate executives, and public and private businesses. Dominari Securities also provides full-service brokerage, wealth planning and margin lending services. Dominari Securities’ investment banking division provides strategic advisory services and capital markets products to middle market businesses.

  • Revenue in USD (TTM)2.04m
  • Net income in USD-22.88m
  • Incorporated1992
  • Employees26.00
  • Location
    Dominari Holdings Inc725 FIFTH AVENUE, 22ND FLOORNEW YORK 10022United StatesUSA
  • Phone+1 (212) 393-4540
  • Fax+1 (302) 674-5266
  • Websitehttps://aikidopharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Imunon Inc0.00-19.51m12.50m33.00--0.9338-----2.17-2.170.001.420.00----0.00-59.23-50.18-80.53-60.27-------5,725.88----0.00---100.00--45.64--26.69--
Monopar Therapeutics Inc0.00-8.40m12.69m10.00--1.94-----0.612-0.6120.000.37490.00----0.00-81.69-54.07-107.13-60.60------------0.00------20.10------
Check Cap Ltd0.00-17.62m12.87m85.00--0.4698-----3.01-3.010.004.680.00----0.00-44.86-58.80-48.21-66.41------------0.00-------11.08--16.04--
Coeptis Therapeutics Holdings Inc0.00-21.27m12.99m5.00--2.95-----0.8922-0.89220.000.12210.00----0.00-266.05-36.90-392.90-37.81------------0.2068------43.40------
NanoViricides Inc0.00-9.36m13.31m7.00--1.15-----0.8004-0.80040.000.98280.00----0.00-55.47-43.54-57.90-46.29------------0.00-------5.94---8.90--
Actavia Life Sciences Inc0.00-4.44m13.35m1.00---------0.0074-0.00740.00-0.00270.00----0.00-10,235.89-158.17---------------21.20---------547.04------
Lotus Pharmaceuticals Inc70.79m1.72m13.47m233.000.09040.00143.490.19030.05530.05532.563.580.632137.2717.85303,836.901.5522.841.7126.4035.1041.622.4519.930.442830.800.05160.0028.7131.70-12.2251.1170.48--
Kiora Pharmaceuticals Inc0.00-13.04m13.48m12.00--0.6474-----2.98-2.980.000.79290.00----0.00-77.27-70.52-91.06-81.86-------2,040.61----0.00------3.97------
Dominari Holdings Inc2.04m-22.88m13.65m26.00--0.2579--6.69-4.44-4.440.38998.920.0305--0.382978,423.08-34.20-26.82-35.10-27.45-----1,122.22-3,353.52----0.00----135.7512.72--63.99--
Pieris Pharmaceuticals Inc42.81m-24.54m13.70m46.00--0.5121--0.3201-22.94-22.9438.0321.640.6382--13.42930,652.20-36.58-28.41-57.30-39.69-----57.33-94.61----0.00--65.288.0326.25---36.82--
Nexgel Inc4.09m-3.16m13.83m19.00--2.71--3.38-0.5566-0.55660.72120.8180.40273.819.57215,263.20-31.39-44.61-38.80-56.1915.165.02-77.95-180.981.46--0.1396--99.6613.0633.48------
Microbot Medical Inc0.00-10.74m14.11m22.00--2.55-----1.08-1.080.000.38450.00----0.00-120.24-53.28-178.87-62.65------------0.00------18.44---31.76--
Data as of May 03 2024. Currency figures normalised to Dominari Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

8.71%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 2023193.39k3.62%
BlackRock Fund Advisorsas of 31 Dec 202375.28k1.41%
Renaissance Technologies LLCas of 31 Dec 202340.73k0.76%
Geode Capital Management LLCas of 31 Dec 202339.23k0.73%
Dimensional Fund Advisors LPas of 31 Dec 202337.38k0.70%
Bridgeway Capital Management LLCas of 31 Dec 202320.50k0.38%
SSgA Funds Management, Inc.as of 31 Dec 202319.99k0.37%
Two Sigma Advisers LPas of 31 Dec 202318.20k0.34%
G1 Execution Services LLCas of 31 Dec 202316.76k0.31%
Tower Research Capital LLCas of 31 Dec 20233.98k0.07%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.